z-logo
open-access-imgOpen Access
Chronic growth stimulation of human adult melanocytes by inflammatory mediators in vitro: implications for nevus formation and initial steps in melanocyte oncogenesis.
Author(s) -
Estela E. Medrano,
Jamal Farooqui,
Raymond E. Boissy,
Ying L. Boissy,
Bola Akadiri,
James J. Nordlund
Publication year - 1993
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.90.5.1790
Subject(s) - melanocyte , carcinogenesis , biology , phenotype , nevus , microbiology and biotechnology , epidermis (zoology) , reversion , inflammation , stimulation , immunology , cancer research , endocrinology , melanoma , genetics , anatomy , cancer , gene
In the human epidermis, melanocytes are distributed at a distance from each other. In contrast, melanocytes in nevi, which are considered benign neoplasms of melanocytes, are grouped in nests. Although still not well defined, environmental factors are thought to play an important role in the development of nevi. We found that chronic growth stimulation by leukotriene C4, a compound found in increased amounts in inflamed skin, induced pleiotropic modifications in the normal melanocyte phenotype. These changes include loss of contact inhibition and formation of structures resembling tumor spheroids. In parallel with these changes, there was a constitutive expression of Fos protein. Switching these cultures to medium supplemented with phorbol ester sustained growth with reversion of the altered phenotype. In contrast, a cAMP stimulator, cholera toxin, induced features of terminal differentiation. Our findings suggest a role for inflammatory mediators in human epidermal melanocytes. This observation provides insight into melanocyte growth alterations which may have relevance in early stages of melanocyte oncogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here